Enbrel

Amgen
Biotech

FDA approves a third biosimilar, with the largest market

The FDA has approved its third biosimilar. This time, it’s for the autoimmune treatment Enbrel, which had $9.5 billion in global sales last year.
Stacy Lawrence Aug 30, 2016 7:38pm
Novartis HQ

Novartis gains FDA panel thumbs up for Amgen Enbrel copy

Jul 14, 2016 7:53am
FDA sign

FDA panel backs Amgen’s Humira copy, but don’t expect to see it anytime soon

Jul 13, 2016 4:46am